myelofibrosis

Novartis: CHMP of the European Medicines Agency adopted a positive opinion for Jakavi® (ruxolitinib) for the treatment of adult patients with polycythemia vera

Polycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and…

9 years ago

Novartis announced patients with myelofibrosis initially randomized to treatment with Jakavi® (ruxolitinib) lived longer

In two Phase III studies, Jakavi ® reduced the risk of death and maintained spleen reductions at three years compared to conventional…

10 years ago